CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination With Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06820957
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:24.774842+00:00
Published At: 2026-02-17T00:00:00+00:00
Record Updated At: 2026-02-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["CIC-Rearranged Sarcoma", "Metastatic Ewing Sarcoma", "Metastatic High Grade Sarcoma", "Metastatic Undifferentiated Round Cell Sarcoma", "Metastatic Undifferentiated Sarcoma, Not Otherwise Specified", "Round Cell Sarcoma With EWSR1-non-ETS Fusion", "Sarcoma With BCOR Genetic Alterations"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-17"
protocolSection.identificationModule.nctId: "NCT06820957"
protocolSection.identificationModule.officialTitle: "Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination With Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients With Newly Diagnosed Metastatic Ewing Sarcoma"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2", "PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.